Social Behavior: Clinical Trials

69 completed, 14 recruiting, 12 unknown, 9 terminated. 116 Phase 2, 22 Phase 1, 9 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	116	Completed 69, Recruiting 14, Unknown 12, Terminated 9, Active not recruiting 4, Not yet recruiting 4, Withdrawn 3, Enrolling by invitation 1
Phase 1	22	Completed 11, Unknown 5, Recruiting 2, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1
Phase 3	9	Completed 5, Recruiting 2, Active not recruiting 1, Terminated 1

Follow Social Behavior: new trials by email Literature Review of Social Behavior trials Research Report on Social Behavior

Trials (filtered) newest first · largest first

All 116 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Lisdexamfetamine For the Treatment of Conduct Disorder in Children Lidexamfetamine - Conduct Disorder	Phase 2	Not yet recruiting	Orygen	30	2027-02-01	2026-11-06
(TNX-1500) in Kidney Transplant Recipients TNX-1500, Kidney Transplant - Kidney Transplant, Kidney Transplant Failure and Rejection	Phase 2	Not yet recruiting	Ayman Al Jurdi, MD	5	2027-01-01	2026-11-06
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome SRX246, Placebo - Aggressive Behavior in Fragile X Syndome	Phase 2	Not yet recruiting	Azevan Pharmaceuticals	80	2026-12-01	2026-10-30
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant Siplizumab, Rabbit anti-thymocyte globulin - Renal Transplant Failure and Rejection	Phase 2	Recruiting	Nefro Avillion Clinical Development, LLC	120	2026-06-29	2026-11-03
Pilot Testing a Novel Approach to Pediatric Obesity Treatment Emotion regulation and self-monitoring to treat pediatric obesity, Psychoeducation - Overweight Adolescents, Obese Adolescents	Phase 1 / Phase 2	Recruiting	Texas Tech University	30	2026-03-24	2026-05-15
Inflammatory Challenge in Human Aggression. Endotoxin (E. coli O:113, Reference Endotoxin), Saline (Placebo) - Intermittent Explosive Disorder	Phase 2	Recruiting	Ohio State University	112	2026-02-16	2026-03-27
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism Propranolol, Placebo - Autism Spectrum Disorder, Challenging Behaviour	Phase 2	Recruiting	Jeremy Veenstra-vanderweele	60	2026-01-30	2026-09-01
The PEDAL Intervention - Reducing Affective Lability in Bipolar Disorder Traditional group psychoeducation for bipolar disorder, Group psychoeducation with digital elements and focus on affective lability - Bipolar Disorder (BD)	Phase 2	Recruiting	Oslo University Hospital	120	2025-12-01	2026-09-04
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection	Phase 2 / Phase 3	Recruiting	Columbia University	150	2025-09-12	2026-10-02
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. hMSC - Alzheimer Disease, Agitation in Dementia	Phase 2	Recruiting	Bernard (Barry) Baumel	8	2025-04-29	2026-05-28
Cultural Adaptation of a Web-Based App (myPlan Thailand) to Empower and Support Friends and Family of Intimate Partner Violence Survivors WeSafe (myPlan Thailand: Friends and Family), DV learning - Intimate Partner Violence (IPV), Social Support	Phase 2	Recruiting	Boromarajonani College of Nursing, Khon Kaen	100	2025-04-17	2025-05-13
Delayed Supine Position Post-Spinal Compared With Immediate Supine Position in Geriatric Patients 2 minutes setting post spinal anesthesia, immediate supine position - we Study the Effect of Keeping the Patient Supine 2 Minutes After Spinal Anesthesia in Geriatric Groups	Phase 2	Completed	Sohar Hospital	90	2025-01-01	2026-04-09
Effort and Antidepressant Study Test Escitalopram 10mg, Placebo 10 mg - Effort Based Decision Making, Prosocial Behavior	Phase 1 / Phase 2	Not yet recruiting	University of Oxford	50	2025-01-01	2024-11-20
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) MEN1703, Glofitamab - Non-Hodgkin Lymphoma, B-cell	Phase 2	Recruiting	Ryvu Therapeutics SA	178	2024-12-05	2026-09-18
Food-Body-Mind Intervention (16 Weeks) Food-Body-Mind - Mental Health Wellness, Emotional Problem	Phase 2 / Phase 3	Recruiting	Michigan State University	800	2024-08-14	2026-10-05
Pimavanserin and Aggression and Social Cognition. Pimavanserin 34 mg, Placebo - Intermittent Explosive Disorder	Phase 2	Recruiting	Ohio State University	35	2024-08-01	2025-03-27
Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders tDCS or Transcranial Direct Current Stimulation, Risperidone, Sham tDCS - Attention, Visual Perceptual Weakness	Phase 1 / Phase 2	Completed	Spanish Foundation for Neurometrics Development	180	2024-04-01	2026-09-10
Feasibility of the JOIN4JOY Programme to Reduce Sedentary Behaviour and Increase Physical Activity in Older Adults. Complex intervention involving physical activity and behaviour change techniques - Physical Inactivity, Sedentary Behavior	Phase 2	Unknown	University of Vic - Central University of Catalonia	144	2023-12-01	2023-11-03
Impact of SGLT2 Inhibitors in Heart Transplant Recipients SGLT2i - Transplant; Failure, Heart, Cardiac Allograft Vasculopathy	Phase 2	Unknown	Universidade Federal do Ceara	80	2023-11-20	2024-05-07
PRISM Race and Communication Pilot RCT Promoting Resilience in Stress Management (PRISM) - Discrimination, Racial, Communication	Phase 1 / Phase 2	Completed	University of Washington	28	2023-07-19	2026-04-30

Showing 20 of 116. Sign in to see all of them.

Narrower conditions

Aggression (40)  ·  Rejection, Psychology (28)  ·  Alzheimer Disease (11)  ·  Psychomotor Agitation (11)  ·  Emotional Regulation (10)  ·  Social Skills (7)  ·  Autism Spectrum Disorder (6)  ·  Depression (6)  ·  Helping Behavior (6)  ·  Autistic Disorder (5)  ·  Social Stigma (5)  ·  Anxiety Disorders (4)  ·  Dementia (4)  ·  Liver Diseases (4)

Broader conditions

Behavior (114)  ·  Behavioral Symptoms (46)  ·  Mental Disorders (41)  ·  Aberrant Motor Behavior in Dementia (39)  ·  Pathological Conditions, Signs and Symptoms (29)  ·  Nervous System Diseases (19)  ·  Neurologic Manifestations (18)  ·  Signs and Symptoms (17)  ·  Neurobehavioral Manifestations (16)  ·  Brain Diseases (13)  ·  Central Nervous System Diseases (13)  ·  Neurodevelopmental Disorders (12)  ·  Pathologic Processes (12)  ·  Urogenital Diseases (12)

Interventions

Tacrolimus (6)  ·  Mycophenolic Acid (5)  ·  Adrenal Cortex Hormones (4)  ·  Luteinizing Hormone, beta Subunit (4)  ·  Sodium Chloride (4)  ·  thymoglobulin (4)  ·  Alemtuzumab (3)  ·  Antilymphocyte Serum (3)  ·  Methylprednisolone (3)  ·  Oxytocin (3)  ·  Prednisone (3)  ·  sotrastaurin (3)  ·  Abatacept (2)  ·  Aripiprazole (2)  ·  Citalopram (2)

Sponsors

Novartis Pharmaceuticals (5)  ·  Merck KGaA, Darmstadt, Germany (4)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Ohio State University (3)  ·  University of Ulm (3)  ·  Arizona State University (2)  ·  Azevan Pharmaceuticals (2)  ·  Indiana University (2)  ·  OPKO Health, Inc. (2)  ·  University of Konstanz (2)  ·  University of Oxford (2)  ·  University of Pittsburgh (2)  ·  Amgen (1)  ·  Avanir Pharmaceuticals (1)  ·  Ayman Al Jurdi, MD (1)

Countries

United States (72)  ·  Canada (14)  ·  Spain (13)  ·  Germany (9)  ·  United Kingdom (9)  ·  France (6)  ·  Belgium (4)  ·  Brazil (3)  ·  Switzerland (3)  ·  Australia (2)  ·  Burundi (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Norway (2)  ·  Poland (2)

Top investigators

Abraham Shaked, MD, PhD (1)  ·  Alexandre A Guerin, PhD (1)  ·  Amy Birney, MPH, MCHES (1)  ·  Amy L Drapalski, PhD (1)  ·  Anas Younes, MD (1)  ·  Andre Strydom, Prof. (1)  ·  Andrew B. Adams, MD, PhD (1)  ·  Anil K Chandraker, MD (1)  ·  Annis Fung, Ph.D. (1)  ·  Anselm Crombach, Dipl.-Psych. (1)  ·  Avi Avital, PhD (1)  ·  Ayman Al Jurdi, MD (1)

Results publications

PMID 27355533, PMID 37811711, PMID 14668458, PMID 14961990, PMID 17564637, PMID 17984842, PMID 18977971, PMID 19487623, PMID 20031032, PMID 20625270, PMID 20673556, PMID 21564523, PMID 21575849, PMID 21702900, PMID 23257314, PMID 24061784, PMID 25062336, PMID 25146492, PMID 25313530, PMID 25468234, PMID 26002873, PMID 27173384, PMID 28744009, PMID 29205343, PMID 29625151, PMID 29859917, PMID 30477544, PMID 30506630, PMID 30999262, PMID 31233321, PMID 31352795, PMID 31414842, PMID 32437738, PMID 32880105, PMID 33234053, PMID 33578648, PMID 33658971, PMID 33823927, PMID 33884617, PMID 33979314, PMID 34059401, PMID 34504446, PMID 35734582, PMID 36636296, PMID 36870019, PMID 36892916, PMID 37322595, PMID 37354201, PMID 37445385, PMID 37732619

NIH funding

2008 (2), 2005 (1), 2018 (1), K23MD015270 (1), K43TW012296 (1), KL2RR025754-04 (1), P30AG024978 (1), R01AG047146 (1), R01DA017295 (1), R01MH059666 (1), R01MH077596 (1), R01MH133925 (1), R21MD017396 (1), R21NS043979 (1), R42MH087322 (1)